The combination of dasatinib, a chemotherapy drug, and quercetin, a flavonoid found in many plants, has emerged as a powerful senolytic therapy. This combination, often referred to as D+Q, has been shown to selectively clear senescent cells, which are known to contribute to aging and a variety of age-related diseases. This article delves into the mechanisms of D+Q as a senolytic, the current research, and its therapeutic potential.
The Rationale for Combining Dasatinib and Quercetin
Dasatinib and quercetin were first identified as a senolytic combination through a screen of a library of compounds for their ability to selectively kill senescent cells. The rationale for combining these two drugs is based on their complementary mechanisms of action. Dasatinib, a tyrosine kinase inhibitor, targets several pathways that are critical for the survival of senescent cells. Quercetin, a flavonoid with antioxidant and anti-inflammatory properties, also has senolytic activity, although its exact mechanism is not as well understood. Together, these two drugs create a potent senolytic cocktail that is effective against a broad range of senescent cell types.
Mechanisms of Senolytic Action
The senolytic activity of D+Q is thought to be mediated by its ability to induce apoptosis in senescent cells. Dasatinib has been shown to inhibit the activity of several tyrosine kinases that are involved in pro-survival pathways in senescent cells. Quercetin is also thought to contribute to the induction of apoptosis, although its mechanism is less clear. It may act by inhibiting the anti-apoptotic protein BCL-xL, similar to fisetin, or by other mechanisms.
Preclinical and Clinical Evidence
The senolytic effects of D+Q have been demonstrated in a variety of preclinical models of aging and disease. In aged mice, D+Q has been shown to reduce the burden of senescent cells, improve physical function, and extend healthspan. D+Q has also been shown to have beneficial effects in models of various age-related diseases, including idiopathic pulmonary fibrosis (IPF), a fatal lung disease. The first human clinical trial of a senolytic, which used D+Q, was published in 2019 and showed that the combination was safe and effective at clearing senescent cells in patients with IPF.
| Study Population | Intervention | Outcome | Reference |
|---|---|---|---|
| Aged Mice | D+Q | Improved physical function | Xu et al., 2018 |
| IPF Patients | D+Q | Reduced senescent cells | Justice et al., 2019 |
| Diabetic Kidney Disease | D+Q | Improved kidney function | Hickson et al., 2019 |
Key Takeaways
- The combination of dasatinib and quercetin (D+Q) is a potent senolytic therapy.
- D+Q selectively clears senescent cells by inducing apoptosis.
- Preclinical and clinical studies have shown that D+Q can improve healthspan and treat age-related diseases.
- D+Q represents a promising new approach to targeting cellular senescence and promoting healthy aging.
References
- Zhu, Y., Tchkonia, T., Pirtskhalava, T., Gower, A. C., Ding, H., Giorgadze, N., ... & Kirkland, J. L. (2015). The Achilles’ heel of senescent cells: from transcriptome to senolytic drugs. Aging cell, 14(4), 644-658.
- Xu, M., Pirtskhalava, T., Farr, J. N., Weigand, B. M., Palmer, A. K., Weivoda, M. M., ... & Kirkland, J. L. (2018). Senolytics improve physical function and increase lifespan in old age. Nature medicine, 24(8), 1246-1256.
- Justice, J. N., Nambiar, A. M., Tchkonia, T., LeBrasseur, N. K., Pascual, R., Hashmi, S. K., ... & Kirkland, J. L. (2019). Senolytics in idiopathic pulmonary fibrosis: results from a first-in-human, open-label, pilot study. EBioMedicine, 40, 554-563.
- Hickson, L. J., Langhi Prata, L. G. P., Bobart, S. A., Evans, T. K., Giorgadze, N., Hashmi, S. K., ... & Kirkland, J. L. (2019). Senolytics decrease senescent cells in humans: a first-in-human, open-label, pilot study. EBioMedicine, 47, 446-456.
Medical Disclaimer: The information provided in this article is for educational purposes only and should not be considered medical advice. Always consult with a qualified healthcare professional before making any decisions about your health or treatment.
